FELIXprinters Announces Commercial Launch of the FELIX BIOprinterMarch 10, 2020
FELIXprinters celebrates 10 yearsOctober 12, 2021
Biofabrication is the use of additive manufacturing or 3D printing technologies for the (re)generation of biological tissues. This scientific field has the potential to revolutionize modern healthcare. However, to reach the life-saving breakthroughs in this very promising field it is very important that researchers, clinicians and the industry have access to the right tools for this endeavour. Therefore, XPECT INX, a spin-off project from Ghent University focuses on the development of innovative new materials for bioprinting. The team at Xpect Inx say: “We believe that the field of bioprinting or biofabrication is in need of reliable innovative materials or ‘bioinks’. Unfortunately, as with a lot of new research fields, there are a lot of innovations happening in academic circles which never bridge the gap to the real world. Therefore, by launching XPECT INX, we aim to capitalize on the years of academic research to bring these innovations to the market. These decades of academic expertise enabled us to develop high quality bio-inks and biomaterials.”
The FELIX BIOprinter offers a reliable platform for BIOprinting, and now, we are proud to announce this new collaboration with XPECT INX. This means a full system approach to BIOprinting with a range of materials for all research and medical needs.
XPECT INX continues: “By tailoring our high quality XPECT INX bioinks for the FELIXbioprinter, we believe that this collaboration has the potential to expand the sum of parts. Via constant mutual developments, we believe that this collaboration reaches far greater than the sum of parts. We believe that this agreement can help to consolidate the first steps towards the future of healthcare.
XPECT INX is available for sale on the FELIXprinters webshop.
For more information about XPECT-INX, visit: www.xpect-inx.com
Contact either the FELIXprinters team at info@felixprinters .com or the XPECT INX team directly at [email protected]